Literature DB >> 24595825

Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation.

Elena Rapizzi1, Tonino Ercolino, Rossella Fucci, Benedetta Zampetti, Roberta Felici, Daniele Guasti, Andrea Morandi, Elisa Giannoni, Valentino Giaché, Daniele Bani, Alberto Chiarugi, Massimo Mannelli.   

Abstract

Paragangliomas (PGLs) are rare neuroendocrine tumours. About 30-40 % of these tumours are mutated in one of the different susceptibility genes, including those encoding the different subunits of the succinate dehydrogenase, a complex involved both in the tricarboxylic acid cycle and in the oxygen transport chain. The aim of this work was to investigate whether SDHB mutations may account for alterations in cell metabolism and functions. Since human PGL cell lines are not available, we used the neuroblastoma cell line (SK-N-AS) stably transfected with the wild-type human SDHB or different SDHB-mutated constructs carrying some significant mutations found in our patients affected by PGLs. Similarly to succinate dehydrogenase (SDH)-mutated tumour cells, mutated SK-N-AS clones showed reduced SDH enzyme activity. All clones showed normal citrate synthase activity, reduced oxygen consumption and reduced carbonic anhydride production, thus demonstrating a decreased in mitochondrial metabolism. In two of the three mutated SK-N-AS, we also found an increase in HIF1α expression. Surprisingly and unexpectedly, in all the SDHB-mutated clones, we found a significant decrease in glucose uptake and in lactate culture medium concentration, suggesting also a decrease of cytosolic metabolism. Finally, we found that these energetic changes were associated to an increase in cell proliferation and migration. Overall, these data demonstrate that although SDHB mutations significantly downregulate both mitochondrial and cytoplasmic cellular metabolism, these mutations are associated to an upregulation of some cellular functions, such as growth rate and invasiveness.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24595825     DOI: 10.1007/s12672-014-0172-3

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  32 in total

1.  Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.

Authors:  Henri J L M Timmers; Anna Kozupa; Graeme Eisenhofer; Margarita Raygada; Karen T Adams; Daniel Solis; Jacques W M Lenders; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2007-01-02       Impact factor: 5.958

Review 2.  Biochemical assays of respiratory chain complex activity.

Authors:  Denise M Kirby; David R Thorburn; Douglass M Turnbull; Robert W Taylor
Journal:  Methods Cell Biol       Date:  2007       Impact factor: 1.441

3.  Sphingosine 1-phosphate differentially regulates proliferation of C2C12 reserve cells and myoblasts.

Authors:  Elena Rapizzi; Chiara Donati; Francesca Cencetti; Paola Nincheri; Paola Bruni
Journal:  Mol Cell Biochem       Date:  2008-05-03       Impact factor: 3.396

4.  Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center.

Authors:  Tuan H Pham; Christopher Moir; Geoffrey B Thompson; Abdalla E Zarroug; Chad E Hamner; David Farley; Jon van Heerden; Aida N Lteif; William F Young
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

Review 5.  Otto Warburg's contributions to current concepts of cancer metabolism.

Authors:  Willem H Koppenol; Patricia L Bounds; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2011-04-14       Impact factor: 60.716

6.  Genetic testing in pheochromocytoma or functional paraganglioma.

Authors:  Laurence Amar; Jérôme Bertherat; Eric Baudin; Christiane Ajzenberg; Brigitte Bressac-de Paillerets; Olivier Chabre; Bernard Chamontin; Brigitte Delemer; Sophie Giraud; Arnaud Murat; Patricia Niccoli-Sire; Stéphane Richard; Vincent Rohmer; Jean-Louis Sadoul; Laurence Strompf; Martin Schlumberger; Xavier Bertagna; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

7.  SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology.

Authors:  P B Douwes Dekker; P C W Hogendoorn; N Kuipers-Dijkshoorn; F A Prins; S G van Duinen; P E M Taschner; A G L van der Mey; C J Cornelisse
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

8.  Phenotype variability of neural crest derived tumours in six Italian families segregating the same founder SDHD mutation Q109X.

Authors:  L Simi; R Sestini; P Ferruzzi; M S Gaglianò; F Gensini; M Mascalchi; L Guerrini; C Pratesi; P Pinzani; G Nesi; T Ercolino; M Genuardi; M Mannelli
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

9.  TORC1 is essential for NF1-associated malignancies.

Authors:  Cory M Johannessen; Bryan W Johnson; Sybil M Genther Williams; Annie W Chan; Elizabeth E Reczek; Ryan C Lynch; Matthew J Rioth; Andrea McClatchey; Sandra Ryeom; Karen Cichowski
Journal:  Curr Biol       Date:  2007-12-27       Impact factor: 10.834

10.  Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function.

Authors:  Chunzhang Yang; Joey C Matro; Kristin M Huntoon; Donald Y Ye; Thanh T Huynh; Stephanie M J Fliedner; Jan Breza; Zhengping Zhuang; Karel Pacak
Journal:  FASEB J       Date:  2012-07-26       Impact factor: 5.191

View more
  6 in total

1.  The Evolving Role of Succinate in Tumor Metabolism: An 18F-FDG-Based Study.

Authors:  Philippe Garrigue; Aurore Bodin-Hullin; Laure Balasse; Samantha Fernandez; Wassim Essamet; Françoise Dignat-George; Karel Pacak; Benjamin Guillet; David Taïeb
Journal:  J Nucl Med       Date:  2017-06-15       Impact factor: 10.057

2.  Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells.

Authors:  Susan Richter; Vanessa D'Antongiovanni; Serena Martinelli; Nicole Bechmann; Maria Riverso; David M Poitz; Karel Pacak; Graeme Eisenhofer; Massimo Mannelli; Elena Rapizzi
Journal:  Cell Tissue Res       Date:  2018-08-29       Impact factor: 5.249

Review 3.  New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.

Authors:  David Taïeb; Karel Pacak
Journal:  Trends Endocrinol Metab       Date:  2017-08-31       Impact factor: 12.015

Review 4.  Energy metabolism in neuroblastoma and Wilms tumor.

Authors:  Sepideh Aminzadeh; Silvia Vidali; Wolfgang Sperl; Barbara Kofler; René G Feichtinger
Journal:  Transl Pediatr       Date:  2015-01

5.  Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models.

Authors:  Petra Bullova; Antony Cougnoux; Luma Abunimer; Juraj Kopacek; Silvia Pastorekova; Karel Pacak
Journal:  Oncotarget       Date:  2016-06-28

6.  Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.

Authors:  Bruna Calsina; Luis Jaime Castro-Vega; Rafael Torres-Pérez; Lucía Inglada-Pérez; Maria Currás-Freixes; Juan María Roldán-Romero; Veronika Mancikova; Rocío Letón; Laura Remacha; María Santos; Nelly Burnichon; Charlotte Lussey-Lepoutre; Elena Rapizzi; Osvaldo Graña; Cristina Álvarez-Escolá; Aguirre A de Cubas; Javier Lanillos; Alfonso Cordero-Barreal; Ángel M Martínez-Montes; Alexandre Bellucci; Laurence Amar; Fabio Luiz Fernandes-Rosa; María Calatayud; Javier Aller; Cristina Lamas; Júlia Sastre-Marcos; Letizia Canu; Esther Korpershoek; Henri J Timmers; Jacques Wm Lenders; Felix Beuschlein; Martin Fassnacht-Capeller; Graeme Eisenhofer; Massimo Mannelli; Fátima Al-Shahrour; Judith Favier; Cristina Rodríguez-Antona; Alberto Cascón; Cristina Montero-Conde; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.